condit
control
inactiv
process
describ
discuss
comput
program
written
assist
use
bel
control
inactiv
viral
antigen
perus
recent
current
literatur
prepar
viral
vaccin
inactiv
antigen
particular
experiment
vaccin
type
show
often
inactiv
still
obtain
formaldehyd
without
necessari
control
prepar
inactiv
viral
vaccin
inactiv
process
import
step
innocu
vaccin
must
assur
question
potenc
address
seem
worthwhil
discuss
inactiv
viral
antigen
refer
older
perhap
forgotten
public
well
recent
studi
procedur
process
control
must
appli
order
assur
safe
inactiv
vaccin
describ
exampl
footandmouth
diseas
fmd
vaccin
prepar
use
vaccin
volum
largest
viral
vaccin
produc
present
mani
year
viral
vaccin
inactiv
antigen
prepar
formaldehyd
inactiv
agent
work
sven
gard
collabor
polioviru
period
demonstr
inactiv
viru
formaldehyd
linear
firstord
reaction
similar
result
obtain
formaldehyd
inactiv
fmd
viru
wesslrn
dinter
grave
recent
public
state
linear
formaldehyd
inactiv
fmd
viru
come
erron
conclus
infect
titrat
inactiv
slope
base
final
read
plaqu
form
unit
pfu
day
far
extend
incub
period
formaldehyd
treat
viru
also
mean
innocu
test
anim
inappropri
detect
small
amount
residu
infecti
viru
viru
begin
reiglic
delay
sever
day
week
anim
alreadi
begin
produc
antibodi
new
viru
neutral
antibodi
anim
abort
subclin
infect
subclin
infect
detect
test
anim
viru
infect
associ
antigen
viaa
viral
rna
polymeras
alonso
et
al
report
studi
cattl
expos
fmd
found
day
postvaccin
anim
vaccin
formaldehyd
inactiv
vaccin
five
anim
posit
viaa
anim
vaccin
nacetylethylenimin
aei
inactiv
vaccin
anim
posit
viaa
pinto
garland
later
found
viaa
posit
case
also
anim
revaccin
aei
inactiv
vaccin
emphas
respons
anim
much
weaker
transient
alonso
et
al
abl
confirm
transient
weak
respons
also
found
binari
ethylenimin
bei
inactiv
ai
oh
oil
adjuv
vaccin
respons
viaa
revaccin
weak
respons
viaa
caus
presenc
antigen
inactiv
viru
suspens
use
vaccin
prepar
howev
viaa
antibodi
induc
safe
inactiv
vaccin
detect
revaccin
presenc
antibodi
primovaccin
still
indic
recent
viru
replic
anim
lucam
et
al
analys
fmd
vaccin
campaign
franc
suspect
residu
infect
formaldehyd
inactiv
fmd
vaccin
pass
offici
innocu
test
recent
beck
strohmaier
studi
virus
field
outbreak
fmd
europ
determin
nucleotid
sequenc
found
isol
relat
viru
strain
formaldehyd
inactiv
vaccin
led
strohmaier
opinion
fmd
outbreak
europ
last
year
homemad
ie
caus
vaccin
made
recommend
inactiv
fmd
vaccin
antigen
chang
formaldehyd
firstord
inactiv
vaccin
stop
altogeth
fmd
vaccin
product
regul
sever
south
american
countri
sever
year
permit
use
firstord
inactiv
least
one
european
countri
recent
also
adopt
posit
fmd
vaccin
product
laboratori
countri
appli
aziridin
compound
ei
form
bei
one
group
laboratori
use
dilut
ei
first
report
bacteri
viru
inactiv
ethylenimin
basic
aziridin
substanc
publish
raettig
uecker
hurst
opinion
vaccin
prepar
aei
inactiv
antigen
superior
vaccin
inactiv
formaldehyd
would
guarante
inactiv
viru
antigen
superior
later
confirm
also
vaccin
inactiv
ici
patent
use
aei
inactiv
microorgan
first
report
inactiv
fmd
viru
aei
publish
brown
crick
also
compound
subsequ
use
lead
fmd
vaccin
product
laboratori
mani
year
prepar
inactiv
antigen
howev
come
gener
use
patent
protect
uecker
report
linear
inactiv
bacteri
virus
ethylenimin
deriv
grave
arlinghau
describ
linear
aei
inactiv
footandmouth
diseas
viru
ambient
temperatur
aei
stabl
therefor
kept
prefer
fellow
remark
aei
low
boil
point
littl
left
biolog
prepar
reaction
temperatur
observ
probabl
made
use
inactiv
temperatur
instead
usual
problem
stabil
aei
perhap
reason
introduc
doubl
dose
regimen
inactiv
ie
applic
two
dose
h
describ
pay
et
al
procedur
still
use
bei
laboratori
although
ei
much
stabl
extend
incub
antigen
damag
antigen
shown
compar
inactiv
fmd
viru
damag
due
inactiv
probabl
caus
action
proteolyt
enzym
present
viru
suspens
laboratori
continu
work
fmd
viru
inactiv
aziridin
earli
report
ethylethylenimin
eei
zg
ethylenimin
binari
ethylenimin
bei
publish
eei
well
difficult
obtain
quantiti
reason
well
eas
prepar
handl
bei
prefer
inactiv
agent
fmd
veterinari
vaccin
virus
report
inactiv
bei
given
tabl
belong
varieti
famili
virus
either
rna
dna
make
like
known
virus
would
inactiv
aziridin
inactiv
vaccin
prepar
transform
infecti
antigen
noninfecti
one
transform
step
therefor
done
well
identifi
intermedi
area
viruscontain
virusfre
area
access
intermedi
area
limit
possibl
viruscontain
side
antigen
must
held
intermedi
area
complet
necessari
control
test
inactiv
endpoint
innocu
facil
hold
inactiv
antigen
area
cold
room
cool
storag
tank
abl
accommod
volum
least
week
product
viru
order
allow
termin
necessari
repeat
control
test
confirm
innocu
antigen
transfer
virusfre
area
use
vaccin
prepar
inactiv
process
done
slow
agit
two
differ
vessel
perhap
one
quarter
third
time
first
vessel
transfer
viru
suspens
inactiv
close
system
second
vessel
remaind
time
procedur
indic
order
avoid
pocket
viru
suspens
inactiv
enter
reinfect
noninactiv
viru
tank
wall
liquid
level
end
inactiv
period
hydrol
inactiv
viru
suspens
check
determin
desir
temperatur
ph
inactiv
ad
also
advis
control
osmolar
viru
suspens
cell
cultur
produc
fmd
viru
mosm
ph
osmolar
viru
suspens
affect
veloc
inactiv
figur
show
result
studi
year
ago
effect
ph
osmolar
inactiv
rate
ei
experiment
condit
given
previous
seen
figur
increas
alkalin
reduc
inactiv
rate
contrast
formalin
inactiv
veloc
inactiv
found
increas
increas
alkalin
figur
show
increas
osmolar
also
slow
inactiv
rate
ph
osmolar
effect
inactiv
rate
perhap
due
conform
chang
viral
capsid
protein
affect
permeabl
inactiv
inactiv
call
binari
ethylenimin
bei
prepar
two
substanc
hbr
bea
naoh
also
distinguish
prepar
pure
ei
bea
convert
alkalin
solut
binari
ethylenimin
activ
substanc
ethylenimin
ring
aziridin
compound
bea
solut
naoh
solut
convers
bei
complet
accompani
ph
drop
format
bei
indirectli
control
visual
chang
ph
indic
flnaphthol
violet
bnv
aqueou
stock
solut
bnv
ml
ad
per
litr
naoh
inactiv
viral
antigen
h
g
bahnemann
solut
colour
bea
solut
chang
min
violet
orang
upon
format
bei
bei
prepar
use
inactiv
colour
chang
orang
ra
bei
prepar
contain
ei
therefor
much
easier
manag
concentr
ei
aei
howev
still
handl
care
prepar
close
vessel
allow
transfer
bei
close
system
inactiv
vessel
higher
concentr
bei
prepar
prepar
handl
bei
solut
requir
much
attent
precaut
el
concentr
much
higher
recommend
use
nathiosulph
hydrolys
bei
bei
inactiv
stop
addit
ofa
ta
steril
nathiosulph
solut
volum
bei
solut
use
also
use
hydrolysationt
bei
spill
clean
vessel
bei
solut
prepar
inactiv
process
must
accompani
appropri
inprocess
control
begin
bei
prepar
describ
format
ethylenimin
ring
monitor
simplifi
manner
necessari
colorimetr
determin
produc
bei
perform
use
method
describ
epstein
et
al
use
czelleng
et
al
bei
preaud
et
al
ei
necessari
colorimetr
determin
bei
prepar
howev
advis
interv
also
control
bea
salt
inform
avail
shelf
life
bea
inactiv
failur
suspect
caus
old
bea
inactiv
virus
bei
first
order
linear
reaction
inactiv
rate
determin
done
take
sampl
infect
titrat
earli
part
inactiv
process
exampl
inactiv
rate
obtain
infect
titr
calcul
regress
coeffici
use
calcul
inactiv
endpoint
endpoint
import
paramet
determin
function
inactiv
rate
reaction
time
volum
viru
suspens
minimum
endpoint
defin
one
log
lower
titr
give
one
infecti
unit
total
volum
inactiv
exampl
one
infecti
unit
volum
one
litr
titr
vaccin
vol
august
inactiv
viral
antigen
h
g
bahnemann
log
usual
express
titr
ml
minimum
endpoint
volum
therefor
log
success
inactiv
calcul
endpoint
lower
minimum
endpoint
differ
calcul
minimum
endpoint
dim
differ
inactiv
endpoint
minimum
valu
posit
import
determin
dim
valu
inactiv
process
assess
success
inactiv
termin
inactiv
viru
suspens
test
innocu
cell
cultur
done
inocul
least
two
roller
bottl
similar
cell
cultur
vessel
two
subsequ
blind
passag
h
interv
cell
cultur
test
prepar
virusfre
area
test
done
intermedi
area
determin
inactiv
endpoint
complet
innocu
test
viru
suspens
consid
properli
inactiv
major
applic
bei
prepar
inactiv
antigen
vaccin
area
bei
use
sinc
bei
react
protein
use
inactiv
adventiti
virus
biolog
prepar
anim
human
tissu
fluid
bei
treatment
bovin
serum
use
cell
cultur
report
use
method
later
confirm
heuschel
appli
period
inactiv
adventiti
bovin
viral
diarrhoea
viru
calf
serum
use
primari
secondari
anim
cell
cultur
bei
also
use
inactiv
virus
enzym
prepar
anim
origin
commerci
trypsin
prepar
treat
bei
without
loss
activ
unpublish
result
like
biolog
like
factor
viii
could
treat
bei
inactiv
adventiti
virus
pure
aziridin
highli
toxic
handl
special
precaut
extrem
care
high
toxic
reason
prepar
bei
molar
bei
prepar
contain
el
vapour
pressur
concentr
low
enough
temperatur
ei
escap
atmospher
boil
point
ei
basi
experi
laboratori
anim
aziridin
consid
carcinogen
substanc
accord
dermer
ham
howev
case
human
cancer
caus
ever
report
fellow
cite
hurst
state
inject
mg
aei
rat
produc
tumour
observ
period
day
total
annual
product
fmd
vaccin
worldwid
probabl
million
dose
nearli
million
dose
produc
south
america
alon
furthermor
fmd
vaccin
inactiv
bei
mean
million
dose
fmd
vaccin
inactiv
bei
appli
cattl
annual
major
cattl
revaccin
mani
time
year
increas
incid
cancer
cattl
vaccin
bei
inactiv
vaccin
ever
report
countri
neither
reason
expect
increas
residu
bei
inactiv
hydrol
nathiosulph
comput
program
written
assist
calcul
need
control
inactiv
virus
bei
firstord
inactiv
screen
menu
program
given
figur
